Systemic Bottlenecks in Drug Discovery: Fragment Screening as a Catalyst for Efficiency
Original framing: “Accelerating drug discovery with fragment screening” — Phys.org
The pharmaceutical industry's prioritization of profit over people has led to a systemic crisis in drug development, with many treatments being developed without adequate consideration for their long-term consequences. This has resulted in a range of negative outcomes, including the over-prescription of opioids and the development of antibiotic-resistant bacteria. By examining the historical context of the pharmaceutical industry, researchers can identify key areas for reform and develop more effective solutions.
The acceleration of drug discovery through fragment screening is a symptom of a broader systemic issue in modern medicine: the inefficient allocation of resources and the lack of interdisciplinary collaboration.
By leveraging advanced technologies and methodologies, researchers can streamline the discovery process, but this alone will not address the underlying structural barriers to innovation. A more comprehensive approach is needed to address the complex challenges in drug development, one that prioritizes the well-being of both people and the planet. This requires the collaboration of researchers from a range of disciplines, the incorporation of traditional knowledge and practices, and a more holistic approach to health. By working together, researchers can develop more effective and sustainable treatments that address the complex challenges in drug development and prioritize the well-being of both people and the planet.